|
|
|
|
| LEADER |
04663nam a22003255i 4500 |
| 001 |
000289013 |
| 005 |
20210909165134.0 |
| 007 |
cr nn 008mamaa |
| 008 |
170328s2017 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319524795
|
| 024 |
7 |
|
|a 10.1007/978-3-319-52479-5
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Proteomic Methods in Neuropsychiatric Research /
|c edited by Paul C. Guest.
|
| 250 |
|
|
|a 1st ed. 2017.
|
| 260 |
# |
# |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2017.
|
| 300 |
|
|
|a XII, 370 p. 55 illus., 45 illus. in color. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Proteomics, Metabolomics, Interactomics and Systems Biology ;
|v 974
|
| 505 |
0 |
|
|a Preface - Proteomic studies in psychiatric disease and neurological disorders -- Part 1: REVIEWS -- Application of proteomic techniques for improved stratification and treatment of schizophrenia patients -- Multiplexing biomarker methods, proteomics and considerations for Alzheimer's disease -- What have proteomic studies taught us about novel drug targets in autism? -- Application of proteomic approaches to accelerate drug development for psychiatric disorders -- Proteomic biomarker identification in cerebrospinal fluid for leptomeningeal metastases with neurological complications -- Connecting brain proteomics with behavioural neuroscience in translational animal models of neuropsychiatric disorders -- LC-MSE for qualitative and quantitative proteomicstudies of psychiatric disorders -- The utility of multiplex assays for identification of proteomic signatures in psychiatry -- Part 2: PROTOCOLS -- Blood sampling and preparation procedures for proteomic biomarker studies of psychiatric disorders -- Multiplex immunoassay profiling of serum in psychiatric disorders -- Sequential immunopreciptation of secretory vesicle proteins from biosynthetically-labelled cells -- 2d gel electrophoresis of insulin secretory granule proteins from biosynthetically-labelled pancreatic islets -- Two-dimensional gel electrophoresis: a reference protocol -- A two-dimensional difference gel electrophoresis (2D-DIGE) protocol for studies of neural precursor cells -- Identifying biomarker candidates in the blood plasma or serum proteome -- Selective reaction monitoring mass spectrometry for quantitation of glycolytic enzymes in post-mortem brain samples -- A selected reaction monitoring mass spectrometry protocol for validation of proteomic biomarker candidates in studies of psychiatric disorders -- Application of iTRAQ shotgun proteomics for measurement of brain proteins in studies of psychiatric disorders -- Co-immunoprecipitation for deciphering protein interactomes -- Sequential co-immunopreciptation and immunoblot approach to determine oligomerisation of G-protein coupled receptors -- A protocol for producing the maternal low protein rat model: a tool for pre-clinical proteomic studies -- A clinical study protocol to identify serum biomarkers predictive of response to antipsychotics in schizophrenia patients -- Generation of the acute phencyclidine rat model for proteomic studies of schizophrenia A protocol for generation of a corticosterone model of psychiatric disorders -- MK-801-treated oligodendrocytes as a cellular model to study schizophrenia -- Combining patient-reprogrammed neural cells and proteomics as a model to study psychiatric disorders -- SILAC mass spectrometry profiling: a psychiatric disorder perspective -- Preparation of peripheral blood mononuclear cells (PBMCs) as a model for proteomic studies psychiatric disorders -- Proteomic profiling of skin fibroblasts as a model of schizophrenia Proteomic profiling of the pituitary gland in studies of psychiatric disorders -- Development of an assay for measuring proprotein-conversion activity on a multiplex magnetic bead-based array platform -- Phenotyping multiple subsets of immune cells in situ in formalin-fixed, paraffin-embedded tissue sections -- Lab-on-a-chip proteomic assays for psychiatric disorders -- Development of a user-friendly app for testing blood coagulation status in schizophrenia patients -- Part 3:FUTURE PERSPECTIVES -- Proteomic approaches to enable point-of-care testing and personalized medicine for psychiatric disorders.
|
| 650 |
|
0 |
|a Proteomics.
|
| 650 |
|
0 |
|a Gene expression.
|
| 650 |
|
0 |
|a Gene therapy.
|
| 650 |
1 |
4 |
|a Proteomics.
|
| 650 |
2 |
4 |
|a Gene Expression.
|
| 650 |
2 |
4 |
|a Gene Therapy.
|
| 700 |
1 |
|
|a Guest, Paul C.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|